{"entity":{"id":"edoxaban","kind":"drug","name":"Edoxaban","aka":[],"tldr":"Edoxaban is a blood-thinning tablet. For a clot in someone with cancer it is started after at least five days of heparin injections.","summary":"The Savaysa label covers stroke prevention in non-valvular atrial fibrillation and treatment of DVT and pulmonary embolism \"following 5 to 10 days of initial therapy with a parenteral anticoagulant\". ITAC 2022 allows edoxaban for initial treatment of VTE in cancer when started after at least 5 days of parenteral anticoagulation, in people without a high risk of gastrointestinal or genitourinary bleeding (1A), and lists edoxaban with rivaroxaban and apixaban among the DOACs recommended for maintenance (1A), with caution in gastrointestinal cancers. The NDA was first approved on 8 January 2015.","status":"approved","asOf":"2026-11-11","wikipedia":"https://en.wikipedia.org/wiki/Edoxaban","links":[{"label":"US label (DailyMed): Savaysa","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e77d3400-56ad-11e3-949a-0800200c9a66"},{"label":"Farge et al., 2022 international clinical practice guidelines (ITAC) for the treatment and prophylaxis of venous thromboembolism in patients with cancer (Lancet Oncol 2022)","url":"https://doi.org/10.1016/S1470-2045(22)00160-7"}],"tags":["supportive","generic","supportive-care-gaps-2026-11"],"related":["apixaban","rivaroxaban"],"cancers":[],"sections":[],"technologies":["cancer-associated-thrombosis"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["vte"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo supportive care gap fill (DailyMed, openFDA, Drugs@FDA, emc SmPCs, NICE, ESMO, ASCO, MASCC, SITC, ASTCT, ITAC, Europe PMC)","editedOn":"2026-11-11"},"brand":"Savaysa / Lixiana","modality":"Direct oral anticoagulant (factor Xa inhibitor, tablet)","supportive":true,"mechanism":"A direct, oral inhibitor of activated factor X.","approvals":[{"region":"US","year":2015,"indication":"Stroke prevention in non-valvular atrial fibrillation; treatment of DVT and PE after 5 to 10 days of parenteral anticoagulation","note":"Year is the original NDA 206316 approval (Drugs@FDA)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/edoxaban/","neighbours":{"drug":[{"id":"apixaban","kind":"drug","name":"Apixaban","route":"/drugs/apixaban/"},{"id":"enoxaparin","kind":"drug","name":"Enoxaparin","route":"/drugs/enoxaparin/"},{"id":"rivaroxaban","kind":"drug","name":"Rivaroxaban","route":"/drugs/rivaroxaban/"}],"technology":[{"id":"cancer-associated-thrombosis","kind":"technology","name":"Cancer-associated thrombosis prevention and treatment","route":"/technologies/cancer-associated-thrombosis/"}],"term":[{"id":"vte","kind":"term","name":"Venous thromboembolism (VTE)","route":"/terms/vte/"}]}}